But abstinence is a large bar comparable to necessitating that an antidepressant create comprehensive remission of melancholy or that an analgesic wholly eliminate discomfort. Recognizing this limitation, the FDA encourages developers of opioid2 and stimulant3 use condition drugs to debate with FDA different ways to measure improvements in drug use